Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis

Nordic Pharma SAS854 enrolled

Overview

This is a longitudinal, observational, prospective, multicentre study conducted in metropolitan France, among a representative sample of office-based or mixed practice rheumatology doctors. The aim of this study is to describe in real life, the therapy strategy when faced with a patient treated with methotrexate as a monotherapy consulting for rheumatoid arthritis and the impact on the progression of the disease at 6 months.

Study Type

OBSERVATIONAL

Enrollment

854

Conditions

Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patient, ambulatory, seen in a rheumatology consultation. * With a confirmed diagnosis of RA (ACR 1987 or ACR/EULAR 2010 criteria) receiving a disease-modifying treatment with methotrexate as a monotherapy. * With clinical, functional, structural and/or therapeutic disease progression, for whom the rheumatologist intends to change the therapeutic treatment of the RA . * Informed about the computer processing of their medical data and their right of access and correction. Exclusion Criteria: * Patient not treated with methotrexate for their RA. * Already treated with a biotherapy or receiving other synthetic DMARDs (disease-modifying antirheumatic drugs) in combination with methotrexate . * Participating in a clinical trial in rheumatology.

Locations (1)

Nordic Pharma

Paris, France

Outcomes

Primary Outcomes

Therapeutic options and Impact on the progression of the disease (EULAR (European League Against Rheumatism) criteria (change in DAS28 (Disease Activity Score 28)

The distribution of the various therapeutic options will be described overall. Their impact on the progression of the RA will be assessed at 6 months according to the EULAR (European League Against Rheumatism) criteria (change in DAS28 (Disease Activity Score 28) score during the study)

Time frame: Patients are included at the time of the change in the treatment of the RA and followed up to 6 months

Secondary Outcomes

Patient's satisfaction using a 4-point verbal scale

Satisfaction will be assessed using a 4-point verbal scale.

Time frame: 6 months after inclusion

Medical economic aspect (cost/benefit ratio)

The cost/benefit ratio of each therapeutic strategy will be described.

Time frame: 6 months after inclusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.